A carregar...
Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer
Ceritinib is the second ALK tyrosine kinase inhibitor after crizotinib, registered in the Russian Federation for the treatment of ALKpositive patients with non-small cell lung cancer (NSCLC). Later alectinib was registered. Thus, we have the opportunity, firstly, to continue targeted therapy with se...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado em: |
Remedium Group LLC
2019-06-01
|
| Colecção: | Медицинский совет |
| Assuntos: | |
| Acesso em linha: | https://www.med-sovet.pro/jour/article/view/3051 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|